A recent article in The Incidental Economist examines new approaches to paying for high-cost gene therapies, focusing on “rev pay” models that spread payments over time rather than requiring a large upfront payment. These models aim to address key challenges such as payer risk, patient mobility between insurers, and the uncertainty around long-term outcomes for one-time therapies. The article cites research from CP3 published in JAMA, describing funding sources for gene therapy trials. As more gene therapies enter the market with multimillion-dollar price tags, these policy and payment models are becoming increasingly important for the sustainability of the health care system.